Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Tamoxifen × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 133 Gynecologic 8 Sarcoma 5 Genitourinary 4 Endocrine 3 CNS 3 Tumor-Agnostic 1 Thoracic 1 Other neoplasm 1 Other 1 NET 1 Lymphoid 1 Gastrointestinal 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 15 Octreotide 8 lutetium Lu 177 dotatate 7 Temozolomide 6 lanreotide 5 Sunitinib 5 Positron Emission Tomography Computed Tomography 5 surufatinib 4 pasireotide 4 gallium Ga 68 dotatate 4 Data Collection 4 3-Iodobenzylguanidine 4 Magnetic Resonance Spectroscopy 3 Etoposide 3 Carboplatin 3 Capecitabine 3 90Y-octreotide, DOTA-Tyr(3)- 3 pentetreotide 2 pembrolizumab 2 pazopanib 2 fosbretabulin 2 fluorodopa F 18 2 avelumab 2 arginyllysine 2 Sorafenib 2 Single Photon Emission Computed Tomography Computed Tomography 2 Pemetrexed 2 PM 01183 2 Irinotecan 2 Ga(III)-DOTATOC 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡